An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)

Trial Profile

An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Bisoprolol (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms BRAVE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top